Reason for R/S: Has to meet the minimum price to stay

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Shifting Gears: GreenCore Solutions Becomes WeFetch.ai Here's a shift you don't see every day. GreenCore Solutions has morphed into WeFetch.ai, aiming to sail the ever-growing AI shopping seas. This isn't just a new nameplate; it's a declaration of intent to dive headfirst into the market dynamics driven by artificial intelligence. It's bold and, frankly, pretty timely....

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

A Triathlete with Grit and Ambition Mako Hiraizumi didn't just earn a silver medal at the 32nd Japan Triathlon National Championships; she set an example of perseverance and ambition. Rising a notch from her bronze finish last year, Hiraizumi's runner-up achievement at Tokyo's Odaiba Seaside Park is no small feat. Yet, she's not resting on her laurels. This athlete from...

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

A Revolutionary Breakthrough for Epidermolysis Bullosa In an incredible achievement for the EB community, Abeona Therapeutics has received FDA approval for ZEVASKYN, which is poised to change the landscape for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). This marks a historic moment as the third FDA-approved treatment for RDEB and the first autologous,...

Zero Candida Marks Milestone with ZC-001 Prototype Production Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) has achieved a remarkable milestone in its quest to revolutionize women's health. The company recently announced the commencement of prototype production for its groundbreaking therapeutic device, ZC-001, designed specifically for the treatment of...

Cautious Optimism for Bitcoin and Other Cryptocurrencies Pseudonymous veteran trader DonAlt expresses a cautious outlook on leading cryptocurrencies like Bitcoin, Ethereum, and Dogecoin. His insights on market trends reveal an intriguing perspective for investors in these digital assets. Current Market Situation DonAlt has recently shared his thoughts on the performance...

Alibaba Reaches Settlement in Lawsuit Alibaba (NYSE: BABA), China’s leading e-commerce powerhouse, has recently taken a significant step in addressing legal challenges by agreeing to pay $433.5 million to settle a class-action lawsuit in the United States. This lawsuit, brought forth by investors, accused Alibaba of engaging in monopolistic practices. The company's...

Understanding the Telix Pharmaceuticals Class Action In a significant development, investors of Telix Pharmaceuticals Limited are currently facing a class action lawsuit. This initiative, spearheaded by Bronstein, Gewirtz & Grossman LLC, invites those affected by substantial losses in their investments to take action. The law firm is renowned for its dedication in...